THE DEMONSTRATION by Mautz in 19361 that procaine, Metycaine and cocaine, locally applied, significantly increase the electrical threshold of heart muscle for premature systoles was followed by the widespread application of procaine as a protective agent in cardiac surgery. The studies of Mautz also initiated investigations designed to test the effectiveness of procaine in the prevention or suppression of cardiac arrhythmias of other origins. The experimental arrhythmias usually were produced in animals by the administration of epinephrine after sensitization with chloroform or cyclopropane. Some authors reported that procaine was effective in preventing ventricular tachycardia and fibrillation which commonly resulted from these procedures,2-5 but Huggins and co-workers6 found that the effects of procaine were too fleeting to be of practical value.6 Zapata-Diaz and co-workers7 terminated auricular paroxysmal tachycardia and ventricular premature systoles in a few cases by intravenous procaine, but failed in other cases of auricular paroxysmal tachycardia, auricular fibrillation, and ventricular tachycardia. These studies were supported in part by a grant H-1109, National Heart Institute, of the National Institutes of Health, U. S. Public Health Service.
Recently, procaine amide (Pronestyl), which is removed from the blood slowly, and which therefore has a prolonged duration of action, has been found more effective in preventing epinephrine-induced arrhythmias in animals and in the treatment of certain types of arrhythmias in patients.8' 9 Procaine amide has been only partially successful in the prophylaxis and therapy of cardiac arrhythmias during thoracic surgery'0 and in the treatment of supraventricular arrhythmias." It has produced distressing toxic reactions including paroxysms of ventricular tachycardia."
The development of a standard technic for producing ventricular tachycardias associated with myocardial infarction in dogs has provided an experimental preparation which re- produces in many important features this grave type of arrhythmia in man.'2-'4 A high frequency ectopic ventricular tachycardia produced by myocardial infarction often has been found difficult to control with drugs most commonly used clinically for this pur- pose,'3 14 therefore the use of such an experimental preparation provides a severe test for the drug being studied. In tests of this kind, procaine proved to be practically useless. Procaine amide was effective in reducing high frequency tachycardias to safely low frequencies, but it would not stop all ectopic activity. Furthermore, it was quite ineffective in certain other animals with lower frequency tachycardias and scattered ectopic ventricular complexes.'5
The effectiveness of procaine amide, though leaving much to be desired, proved that drugs in the local anesthetic group could be of practical value in the suppression of high frequency ectopic rhythms resulting from cardiac pathology. Since only procaine and procaine amide of this series of chemically related compounds had been tested with animal preparations of this kind, it appeared important that the studies be extended to other drugs of the cocaine-like group. Nupercaine hydrochloride* was chosen for testing in a new series of experiments because of its high potency as a local and spinal anesthetic, and its long duration of action. TECHNICS Myocardial infarction was produced in 22 An effort was made to administer the minimal quantity of Nupercaine necessary to achieve this result.
RESULTS

Nupercaine Alone
The intravenous administration of Nupercaine to four unanesthetized animals with ventricular tachycardia on the first day after occlusion and to 18 on the second day produced ectopic impulse suppressor action in every case. In all of the four first postocclusion-day tests and some of the second postocclusion-day tests with Nupercaine alone the reduction of frequency of ectopic complexes was accompanied by toxic reactions. The toxic manifestations were retching, vomiting, and convulsive movements. Retching and vomiting occurred in all first day tests with Nupercaine alone. Convulsive movements occurred in two of the four animals. Figure 1 , the chart of the first experiment with Nupercaine, illustrates both the ectopic suppressor action and the incidence of vomiting in a dog with a moderately high frequency ventricular tachycardia. More complete suppression of the arrhythmia undoubtedly could According to the criterion of success, previously defined, all of the first postocclusion-day tests with Nupercaine alone could be classified as just barely successful. The ectopic frequencies could be maintained at levels about one half of the pretreatment ectopic rates or slightly less for periods up to four hours, but the toxic reactions were distressing. The second postocclusion-day results will be further analyzed in succeeding sections.
Nupercaine Following Morphine
The effects of Nupercaine were tested following administration of morphine in figure 4 are from the animal which exhibited the highest ectopic frequency prior to treatment in this series of experiments. The chart in figure 5 presents in detail the data from this experiment.
The record in figure 4A was taken just prior The results in the other experiments with Nupercaine following pentobarbital sodium were similar to those represented by this experiment. Both Nupercaine because no normal complexes existed. In experiment 22 after some normal cycles were restored by Nupercaine, 1 mg. per kilogram, the duration of P-R was 0.10 second and that of QRS was 0.05. At the end of the infusion of the total amount of Nupercaine required for control of the ectopic activity, 8 mg. per kilogram, P-R was 0.12 and QRS was 0.06 second. These small increases are only slightly greater than the range of spontaneous variations and are not indicative of dangerous effects. The data for experiment 17 show no prolongation of P-R and the increase in QRS is similar to that in experiment 22.
observed. Figure 6B illustrates one such episode. The onset of the broad complexes and pressure decline occurred after the infusion of Nupercaine, 7 mg. per kilogram at a rate of 4 mg. per kilogram per hour. Recovery of normal duration of QRS complexes and of mean blood pressure to a level higher than the control occurred promptly upon suspending the infusion (fig. 6C, 30 seconds after B) .
No deaths occurred in the 22 dogs with ventricular tachycardia accompanying myocardial infarction during tests with Nupercaine alone or in combination with morphine, phenobarbital, or pentobarbital. P-R and QRS durations showed only minor alterations in such tests. In some rapid administration tests, periods of prolonged QRS deflections and hypotension occurred. Upon stopping the fast infusion all signs returned to normal within 30 seconds.
The phenobarbital-Nupercaine combination is regarded as an effective and relatively safe combination for the treatment of ventricular tachycardia accompanying myocardial infarction when suitable precautions are observed.
SUMARIO ESPAROL En 22 perros con taquicardia ventricular acompafiada de infarto del miocardio, hidrocloruro de Nupercaina se encontro ser un supresor potente de impulsos ect6picos. Cuando la Nupercaina se usa sola tambidn produce v6mitos y movimientos convulsivos. Cuando se combin6 con morfina, los vomitos se eliminaron pero las convulsiones no. Cuando se combin6 con fenobarbital s6dico o pentobarbital sodico, la accion de suprimir impulsos ect6-picos fu6 aumentada y los v6mitos y convulsiones suprimidos. La duracion de la acci6n de suprimir los impulsos ect6picos fu6 significativamente mayor en el experimento con fenobarbital yNupercaina que en ningun otro grupo. Ninguna muerte ocurrio en los 22 perros.
